🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great write-up about us and our launch in TechCrunch! techcrunch.com/2021/12/07/nab…

“We’re in the first five years of developability being recognized as one of the main reasons antibodies are failing in the clinic.” Nabla Bio is using #AI to design antibodies with therapeutic potential AND optimal biophysical properties. techcrunch.com/2021/12/07/nab… #BuiltOnBenchling

Beep boop 🤖 Very excited to share two new computational roles at Nabla! - 3D / Structural ML Scientist - Software Engineer bit.ly/3skpwmI

Introducing the Spinout Playbook, a free guide to spinning a startup out of academia. fiftyyears.com/spinout Why is this needed? The process of “spinning out” science from universities is broken 👇🧵

Today we announce the close of a $26M Series A financing, led by Radical Ventures with participation from all existing investors, and pharmaceutical collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda. Thanks to Endpoints News for breaking our news. endpts.com/exclusive-astr…

Excited to share Nabla Bio is partnering with 3 of the world’s largest pharma cos to use integrated AI and wet-lab tech to design antibodies against challenging disease targets. Thrilled to also add Radical Ventures who led our $26M Series A to the family! bit.ly/4dDk4lP

I’m speaking today at PEGS Summit, 5:10 pm, Eng Antibodies. Talk will cover new “solMPMP” tech from Nabla Bio where we use generative ML to create soluble proxies of valuable multipass membrane protein drug targets, and use these proxies to facilitate design of new biologics.

AI investor Dylan Reid of Zetta Ventures(NOETIK & Nabla Bio in portfolio) posted ahead of #JPM25 on what he's paying attention to in life sci incl Data Generation-as-a-Service, Open Source Wars, Multiscale Models & "Agents Everywhere (but the Lab)". linkedin.com/posts/deploy_i…

great and thorough post on one way we Nabla Bio are designing antibodies to multipass membrane proteins, a high-impact but difficult to drug class of proteins

Our own Adithya Paramasivam will be giving a talk on our work in de novo antibody design at the BioLogic Summit in San Diego next week. Looks like it will be a great event!

Tech report of our de novo antibody design platform, JAM, is now up on biorxiv! We added new results showing JAM-generated sequences and structures are quite novel. Link below

Rockets, AI weather balloons, self-driving trucks… just a few of the KV companies that made Fast Company’s Most Innovative lists. Rocket Lab Speak WindBorne Systems OpenAI Nabla Bio Imprint Payments Waabi fastcompany.com/most-innovativ…

Alli will be giving a talk about some of our latest results on antibody design for GPCRs, and the protein production and characterization challenges that go along with that at PEGS Boston 9AM Monday.

Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox Debates over terminology clouded the mission of bringing better therapeutics to the clinic faster Nabla Bio HHMI Baker Lab Absci Generate:Biomedicines Caltech hubs.ly/Q03nqpw_0